Technical Report Health Risks of POPs from LRTAP

Transcription

1 Joint Task Force of WHO/ECEH and Executive Body for the CLRTAP on Health Aspects of LRTAP Technical Report Health Risks of POPs from LRTAP Lindita Tafaj On behalf of WHO W ECEH Bonn Office

2 Members of the Working Group Ruth Alcock,, UK Vladimir Bashkin,, Russia Michèle Bisson, France Leendert van Bree, Netherlands Radovan Chrast,, UN/ECE Claudio Colosio,, Italy Hélène Desqueyroux,, France Elena Evstafjeva,, Ukraine Mark Feeley,, Canada Greg Filyk,, Canada Ramon Guardans,, Spain Helen Hakansson,, Sweden Thomas Hausmann,, Germany Ivan Holoubek,, Czech Republic Marek Jakubowski,, Poland Niklas Johansson, Sweden Blanka Krauthacker,, Croatia Berit Kvaeven,, Norway Tamas Lotz,, Hungary Alexander Malanichev,, Russia Nicolae Opopol,, Moldova Annick Pichard,, France Irina Pichsheva,, Kazakhstan Theresa Repaso-Subang Subang,, Canada Martin Schlabach,, Norway Ion Shalaru,, Moldova Stefan Seum,, Germany David Stone, Canada Peter Straehl,, Switzerland Carolyn Vickers, IPCS, WHO-Geneva WHO Secretariat WHO/ECEH Bonn: Michal Krzyzanowski Emilia Niciu Lindita Tafaj

3 Milestones December 1999 May Dec Request of Executive Body for CLRTAP for a preliminary selection of prority POPs (TFH) 3 rd TFH Meeting: Selection of POPs, planning POPs review 4 th TFH Meeting: review of 1 st Draft Technical Report, preliminary structure of chapters April nd Draft TR distributed for review 26 April 2002 Drafting group meeting (outline of Technical and Summary Report) May th TFH Meeting: review & approval of the 2nd Draft TR + ExSum May 2002 ExSum submitted to WGE August 2002 ExSummeries presented to WGE for approval

4 Selected chemicals: Human health implications related to long range transport of: 1. Pentachlorophenol (PCP) 2. DDT 3. γ-hch (lindane) and β-hch 4. Hexachlorobenzene (HCB) 5. Heptachlor 6. Polychlorinated dibenzo-dioxins/ -furans and dioxin-like PCBs 7. Polychlorinated biphenyls (PCBs) 8. Polycyclic aromatic hydrocarbons (PAHs) 9. Polychlorinated terphenyls (PCTs) and ugilec*) 10. Polybrominated diphenylethers (Pentha-) *) 11. Polybrominated dibenzodioxins and furans*) 12. Short-chain chlorinated paraffins *) *) Short hazard assessment only

5 Format: Comprehensive, easily accessible overview of health risks of the pollutant. Key question: To which extend LRTAP of POPs contributes to the health risk?

6 Structure of the Technical Report: Summary report official WGE Document 1. Introduction 2. Chapters specific for each group of substances

7 Outline of the chapter (drafting group): 1. Introduction Why substance included in the assessment, status in POPs Protocol? 2. Characteristics of a substance as a POP with LRTAP potential Physical properties allowing atmospheric transport, persistence, bioaccumulation, monitoring and modeling.. 3. Pathways of human exposure and its relation to LRTAP Sources of human exposure, exposure levels (highly exposed groups).. 4. Health hazard characterization Toxicokinetiks (absorption, distribution, metabolism,..), effects on laboratory animals and in humans, existing reference values.. 5. Human health implications relative to LRTAP Synthesis of conclusions on 3 and 4: contribution of LRTAP to the exposure and related health risk

8 Conclusions of the assessment: Pollutant 1. PCP 2. DDT 3. HCH (Lindane) 4. HCB 5. Heptachlor 6. PCDDs/PCDFs Human health risk related to LRTAP Potential for health effects at low level chronic exposure (oral). Potential for LRTAP. Further research needed to assess the significance of LRTAP to human exposure. LRTAP main source of exposure and consequent health implications for populations in remote areas Large reservoirs in environment. Possible risk to health through LRTAP. Still released to the environment in the LRTAP Convention (unintentional emissions: waste incineration, manufacturing..) Health effects potentially related to low-level chronic exposure. General population not at risk from LRTAP derived heptachlor. «High risk» groups (some breast-fed infants, Arctic Inuit ). Increased risk of harmful health effects in the general population, especially breastfed infants and populations with specific diets. LRTAP is expected to contribute significantly to exposure and health risks.

9 Conclusions of the assessment: Pollutant Human health risk related to LRTAP 7. PCBs 8. PAHs 9. PCTs 10. PBDEs 11. PBDD/F*) 12. SCCPs *) Increased health risks from current exposures. LRTAP is expected to contribute significantly to exposure and health risks, especially in remote areas. Increased risk of harmful effects. Health risks attributed to LRTAP is low compared to the risk due to local sources. Insufficient information to evaluate health implications from LRTAP «At risk» groups: developing fœtus, breastfed infants. LRTAP would be substantial for remote locations. Insufficient information Not conclusive. LRTAP is an important aspect of the global distribution of SCCP and is responsible for their occurrence in remote areas. EU risk assesssment report no significant risk to humans exposed via environment.

10 Authors of the 2 nd Draft Pollutant 1. PCP 2. DDT 3. HCH (Lindane) 4. HCB 5. Heptachlor 6. PCDDs/PCDFs 7. PCBs 8. PAHs 9. PCTs *) 10. PBDE*) 11. PBDD/F*) 12. SCCPs *) Responsible A. Pichard M. Bisson C. Colosio A. Pichard, M. Bisson V. Bashkin R. Alcock N. Johansson H. Hakansson M. Jakubowski T. Repaso-Subang M. Feeley N. Johansson M. Schalbach R. Alcock R. Guardans, R. Alcock, E. Estafaeva, M. Feeley, R. Guardans, H. Hakansson, N. Opopol R. Alcock, C. Colosio, E. Estafaeva, R. Guardans, N. Opopol R. Alcock, C. Colosio, E. Estafaeva R. Guardans R. Alcock, R. Guardans, I. Holoubek, H. Hakansson R. Alcock, R. Guardans, I. Holoubek, N. Johansson R. Alcock, L. van Bree, R. Guardans, I. Holoubek G. Filyk N. Johansson H. Hakansson R. Alcock Co-authors

11 http: // int/document/e /document/e78963.pdf Thank you!